Chronic Refractory Idiopathic Urticaria ()
Affiliation(s)
1Department of Internal Medicine, MedStar Union Memorial Hospital, Baltimore, Maryland, USA.
2Department of Internal Medicine, William Beaumont Hospital, Royal Oak, Michigan, USA.
3Department of Internal Medicine, MedStar Good Samaritan Hospital, Baltimore, Maryland, USA.
ABSTRACT
Background: Chronic spontaneous urticaria (CSU) is a complex medical condition characterized by substantial morbidity and a negative impact on one’s quality of life. There are several treatment approaches available, tailored to the severity of the condition, which can enhance overall quality of life. Aim: In this article, we outline a systematic approach to managing chronic urticaria, while also elucidating the available treatment strategies for cases that prove resistant to conventional therapies. To illustrate our points, we present a clinical case as a practical example. Case Presentation: Here, we present a patient with CSU since childhood who presented in the context of refractory hives and generalized arthralgia that responded well to omalizumab therapy with no further relapse. Conclusion: Omalizumab is a biological agent that offers a potential treatment option for CSU. It is available for individuals twelve years and older who have not responded well to conventional treatments. It has demonstrated good efficacy with a relatively low rate of clinically significant adverse effects. Nonetheless, there is a dearth of research regarding the optimal method for tapering the dosage and determining the duration of treatment.
Share and Cite:
Acharya, I. , Pokharel, A. , Pokharel, A. and Smith, L. (2023) Chronic Refractory Idiopathic Urticaria.
Journal of Biosciences and Medicines,
11, 13-22. doi:
10.4236/jbm.2023.1111002.
Cited by
No relevant information.